Flippin Bruce & Porter Has Boosted Its Nucor (NUE) Holding; Karyopharm Therapeutics (KPTI) Sellers Decreased By 2.94% Their Shorts

February 17, 2018 - By Linda Rogers

Karyopharm Therapeutics Incorporated (NASDAQ:KPTI) had a decrease of 2.94% in short interest. KPTI’s SI was 2.21M shares in February as released by FINRA. Its down 2.94% from 2.28M shares previously. With 108,100 avg volume, 20 days are for Karyopharm Therapeutics Incorporated (NASDAQ:KPTI)’s short sellers to cover KPTI’s short positions. The SI to Karyopharm Therapeutics Incorporated’s float is 11.08%. The stock increased 1.42% or $0.21 during the last trading session, reaching $14.98. About 377,939 shares traded or 78.29% up from the average. Karyopharm Therapeutics Inc. (NASDAQ:KPTI) has risen 21.19% since February 17, 2017 and is uptrending. It has outperformed by 4.49% the S&P500.

Flippin Bruce & Porter Inc increased Nucor Corp (NUE) stake by 1801.96% reported in 2017Q3 SEC filing. Flippin Bruce & Porter Inc acquired 77,971 shares as Nucor Corp (NUE)’s stock declined 11.33%. The Flippin Bruce & Porter Inc holds 82,298 shares with $4.61 million value, up from 4,327 last quarter. Nucor Corp now has $21.79 billion valuation. The stock increased 4.51% or $2.96 during the last trading session, reaching $68.54. About 5.31 million shares traded or 71.13% up from the average. Nucor Corporation (NYSE:NUE) has risen 21.74% since February 17, 2017 and is uptrending. It has outperformed by 5.04% the S&P500.

Since September 19, 2017, it had 0 buys, and 3 selling transactions for $1.59 million activity. 15,131 shares were sold by FERRIOLA JOHN J, worth $913,959 on Monday, October 23. $137,912 worth of Nucor Corporation (NYSE:NUE) shares were sold by HAYNES VICTORIA F. 9,003 shares were sold by Utermark D. Chad, worth $537,659 on Friday, October 27.

Among 19 analysts covering Nucor Corporation (NYSE:NUE), 12 have Buy rating, 0 Sell and 7 Hold. Therefore 63% are positive. Nucor Corporation had 80 analyst reports since July 22, 2015 according to SRatingsIntel. The company was downgraded on Tuesday, September 12 by Morgan Stanley. The firm has “Buy” rating by Barclays Capital given on Friday, April 21. The rating was maintained by Cowen & Co with “Market Perform” on Monday, October 26. Morgan Stanley upgraded Nucor Corporation (NYSE:NUE) on Monday, February 13 to “Overweight” rating. On Wednesday, May 24 the stock rating was upgraded by Credit Suisse to “Outperform”. The firm earned “Buy” rating on Friday, October 20 by Citigroup. Bank of America downgraded the stock to “Neutral” rating in Wednesday, July 20 report. The firm has “Equal-Weight” rating given on Tuesday, February 6 by Morgan Stanley. Barclays Capital maintained Nucor Corporation (NYSE:NUE) rating on Monday, February 6. Barclays Capital has “Overweight” rating and $67 target. Deutsche Bank maintained the shares of NUE in report on Monday, December 5 with “Buy” rating.

Investors sentiment decreased to 0.89 in Q3 2017. Its down 0.35, from 1.24 in 2017Q2. It dropped, as 62 investors sold NUE shares while 223 reduced holdings. 59 funds opened positions while 196 raised stakes. 232.46 million shares or 1.40% less from 235.76 million shares in 2017Q2 were reported. Hsbc Holdg Public Limited Company holds 0.06% or 645,348 shares in its portfolio. 50,470 were accumulated by Catawba Mngmt Va. Ahl Llp owns 0.27% invested in Nucor Corporation (NYSE:NUE) for 265,100 shares. Moreover, Comerica Securities has 0.66% invested in Nucor Corporation (NYSE:NUE). Van Eck Associates has 0.04% invested in Nucor Corporation (NYSE:NUE) for 137,909 shares. Eastern State Bank has 3,856 shares for 0.02% of their portfolio. Prudential Public Limited Company invested 0.44% of its portfolio in Nucor Corporation (NYSE:NUE). Twin Tree Mgmt Lp accumulated 33,779 shares. Pggm Investments reported 80,904 shares. Tiverton Asset Management Ltd Liability Com has 0.01% invested in Nucor Corporation (NYSE:NUE). 1,000 are owned by Perkins Coie Tru. Bartlett And Limited holds 0% or 1,101 shares in its portfolio. Moreover, San Francisco Sentry Invest Grp (Ca) has 0.01% invested in Nucor Corporation (NYSE:NUE). Blb&B Advisors Limited Liability Corporation reported 4,463 shares. Moreover, Gemmer Asset Limited Company has 0% invested in Nucor Corporation (NYSE:NUE).

Among 13 analysts covering Karyopharm Therapeutics Inc. (NASDAQ:KPTI), 12 have Buy rating, 1 Sell and 0 Hold. Therefore 92% are positive. Karyopharm Therapeutics Inc. had 28 analyst reports since August 11, 2015 according to SRatingsIntel. As per Tuesday, June 28, the company rating was initiated by Robert W. Baird. The firm has “Buy” rating by Jefferies given on Wednesday, September 9. The stock of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) has “Hold” rating given on Wednesday, January 6 by Jefferies. The firm has “Buy” rating given on Thursday, January 11 by H.C. Wainwright. H.C. Wainwright maintained it with “Buy” rating and $23.0 target in Tuesday, December 12 report. The company was maintained on Tuesday, August 11 by Leerink Swann. The stock of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) earned “Buy” rating by RBC Capital Markets on Thursday, November 2. The company was maintained on Monday, March 14 by JP Morgan. On Tuesday, August 30 the stock rating was upgraded by Jefferies to “Buy”. The stock has “Buy” rating by Cantor Fitzgerald on Friday, June 23.

Investors sentiment increased to 2.5 in Q3 2017. Its up 0.94, from 1.56 in 2017Q2. It improved, as 5 investors sold Karyopharm Therapeutics Inc. shares while 11 reduced holdings. 7 funds opened positions while 33 raised stakes. 27.91 million shares or 3.47% more from 26.98 million shares in 2017Q2 were reported. State Street has 0% invested in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) for 556,443 shares. Schwab Charles Investment Inc reported 140,360 shares stake. United Svcs Automobile Association has 79,055 shares for 0% of their portfolio. C Ww Wide Group Holdg A S holds 0% in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) or 18,515 shares. 21,911 are held by Metropolitan Life Ins Ny. Credit Suisse Ag holds 32,039 shares. Dimensional Fund Advsr L P invested in 0% or 319,042 shares. New York State Common Retirement Fund, a New York-based fund reported 30,500 shares. Alliancebernstein Ltd Partnership owns 43,430 shares. Great West Life Assurance Can has 0% invested in Karyopharm Therapeutics Inc. (NASDAQ:KPTI). First Personal invested in 0% or 1,187 shares. Millennium Mngmt Limited Liability Corp reported 370,916 shares. Royal Bancorporation Of Canada reported 3,669 shares. Iguana Health Mgmt Ltd Llc holds 2.45% or 400,000 shares. Barclays Public Limited Company stated it has 0% of its portfolio in Karyopharm Therapeutics Inc. (NASDAQ:KPTI).

Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. The company has market cap of $742.01 million. The Company’s lead drug candidate is Selinexor, which is in Phase IIb clinical trial for patients with heavily pretreated multiple myeloma; Phase Ib/II clinical study in combination with backbone treatments for relapsed/refractory multiple myeloma; Phase II/III clinical trial for patients with relapsed and/or refractory multiple myeloma; Phase II clinical study to treat acute myeloid leukemia; Phase IIb clinical trial for patients with diffuse large B-cell lymphoma; and Phase II/III clinical trial to treat liposarcoma. It currently has negative earnings. The firm is also developing KPT-8602 that is in Phase I/II study for patients with relapsed/refractory multiple myeloma; KPT-9274, which is in Phase I clinical trial for patients with advanced solid malignancies or non-HodgkinÂ’s lymphoma; KPT-335, which is in Phase I clinical trial for the treatment of viral indications; and KPT-350 that is in preclinical stage to treat neurological disorders, and inflammatory and autoimmune diseases.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


>